215 related articles for article (PubMed ID: 31470862)
21. Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ß-lapachone.
Chakrabarti G; Moore ZR; Luo X; Ilcheva M; Ali A; Padanad M; Zhou Y; Xie Y; Burma S; Scaglioni PP; Cantley LC; DeBerardinis RJ; Kimmelman AC; Lyssiotis CA; Boothman DA
Cancer Metab; 2015; 3():12. PubMed ID: 26462257
[TBL] [Abstract][Full Text] [Related]
22. Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer.
Emmanouilidi A; Fyffe CA; Ferro R; Edling CE; Capone E; Sestito S; Rapposelli S; Lattanzio R; Iacobelli S; Sala G; Maffucci T; Falasca M
J Exp Clin Cancer Res; 2019 May; 38(1):191. PubMed ID: 31088502
[TBL] [Abstract][Full Text] [Related]
23. Phellodendrine chloride suppresses proliferation of KRAS mutated pancreatic cancer cells through inhibition of nutrients uptake via macropinocytosis.
Thu PM; Zheng ZG; Zhou YP; Wang YY; Zhang X; Jing D; Cheng HM; Li J; Li P; Xu X
Eur J Pharmacol; 2019 May; 850():23-34. PubMed ID: 30716311
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer.
Adamska A; Domenichini A; Capone E; Damiani V; Akkaya BG; Linton KJ; Di Sebastiano P; Chen X; Keeton AB; Ramirez-Alcantara V; Maxuitenko Y; Piazza GA; De Laurenzi V; Sala G; Falasca M
J Exp Clin Cancer Res; 2019 Aug; 38(1):312. PubMed ID: 31378204
[TBL] [Abstract][Full Text] [Related]
25. Treatment of Pancreatic Cancer Patient-Derived Xenograft Panel with Metabolic Inhibitors Reveals Efficacy of Phenformin.
Rajeshkumar NV; Yabuuchi S; Pai SG; De Oliveira E; Kamphorst JJ; Rabinowitz JD; Tejero H; Al-Shahrour F; Hidalgo M; Maitra A; Dang CV
Clin Cancer Res; 2017 Sep; 23(18):5639-5647. PubMed ID: 28611197
[No Abstract] [Full Text] [Related]
26. SOX2 functions as a molecular rheostat to control the growth, tumorigenicity and drug responses of pancreatic ductal adenocarcinoma cells.
Wuebben EL; Wilder PJ; Cox JL; Grunkemeyer JA; Caffrey T; Hollingsworth MA; Rizzino A
Oncotarget; 2016 Jun; 7(23):34890-906. PubMed ID: 27145457
[TBL] [Abstract][Full Text] [Related]
27. Targeted Inhibition of Glutamine-Dependent Glutathione Metabolism Overcomes Death Resistance Induced by Chronic Cycling Hypoxia.
Matschke J; Riffkin H; Klein D; Handrick R; Lüdemann L; Metzen E; Shlomi T; Stuschke M; Jendrossek V
Antioxid Redox Signal; 2016 Jul; 25(2):89-107. PubMed ID: 27021152
[TBL] [Abstract][Full Text] [Related]
28. Glutamine mimicry suppresses tumor progression through asparagine metabolism in pancreatic ductal adenocarcinoma.
Recouvreux MV; Grenier SF; Zhang Y; Esparza E; Lambies G; Galapate CM; Maganti S; Duong-Polk K; Bhullar D; Naeem R; Scott DA; Lowy AM; Tiriac H; Commisso C
Nat Cancer; 2024 Jan; 5(1):100-113. PubMed ID: 37814011
[TBL] [Abstract][Full Text] [Related]
29. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice.
Song X; Zhu S; Xie Y; Liu J; Sun L; Zeng D; Wang P; Ma X; Kroemer G; Bartlett DL; Billiar TR; Lotze MT; Zeh HJ; Kang R; Tang D
Gastroenterology; 2018 Apr; 154(5):1480-1493. PubMed ID: 29248440
[TBL] [Abstract][Full Text] [Related]
30. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
Xue A; Xue M; Jackson C; Smith RC
Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314
[TBL] [Abstract][Full Text] [Related]
31. The novel Trk receptor tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits antitumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness.
Miknyoczki SJ; Dionne CA; Klein-Szanto AJ; Ruggeri BA
Ann N Y Acad Sci; 1999 Jun; 880():252-62. PubMed ID: 10415871
[TBL] [Abstract][Full Text] [Related]
32. The discovery of a non-competitive GOT1 inhibitor, hydralazine hydrochloride, via a coupling reaction-based high-throughput screening assay.
Wu Q; Sun Z; Chen Z; Liu J; Ding H; Luo C; Wang M; Du D
Bioorg Med Chem Lett; 2022 Oct; 73():128883. PubMed ID: 35820623
[TBL] [Abstract][Full Text] [Related]
33. KRas4B-PDE6δ complex stabilization by small molecules obtained by virtual screening affects Ras signaling in pancreatic cancer.
Casique-Aguirre D; Briseño-Díaz P; García-Gutiérrez P; la Rosa CHG; Quintero-Barceinas RS; Rojo-Domínguez A; Vergara I; Medina LA; Correa-Basurto J; Bello M; Hernández-Rivas R; Del RocioThompson-Bonilla M; Vargas M
BMC Cancer; 2018 Dec; 18(1):1299. PubMed ID: 30594165
[TBL] [Abstract][Full Text] [Related]
34. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
[TBL] [Abstract][Full Text] [Related]
35. Targeting aspartate aminotransferase in breast cancer.
Thornburg JM; Nelson KK; Clem BF; Lane AN; Arumugam S; Simmons A; Eaton JW; Telang S; Chesney J
Breast Cancer Res; 2008; 10(5):R84. PubMed ID: 18922152
[TBL] [Abstract][Full Text] [Related]
36. Unique metabolic features of pancreatic cancer stroma: relevance to the tumor compartment, prognosis, and invasive potential.
Knudsen ES; Balaji U; Freinkman E; McCue P; Witkiewicz AK
Oncotarget; 2016 Nov; 7(48):78396-78411. PubMed ID: 27623078
[TBL] [Abstract][Full Text] [Related]
37. c-Myc protects hepatocellular carcinoma cell from ferroptosis induced by glutamine deprivation via upregulating GOT1 and Nrf2.
Zhao Y; Wang Y; Miao Z; Liu Y; Yang Q
Mol Biol Rep; 2023 Aug; 50(8):6627-6641. PubMed ID: 37358765
[TBL] [Abstract][Full Text] [Related]
38. MiR-143-3p suppresses tumorigenesis in pancreatic ductal adenocarcinoma by targeting KRAS.
Xie F; Li C; Zhang X; Peng W; Wen T
Biomed Pharmacother; 2019 Nov; 119():109424. PubMed ID: 31521891
[TBL] [Abstract][Full Text] [Related]
39. UBL4A inhibits autophagy-mediated proliferation and metastasis of pancreatic ductal adenocarcinoma via targeting LAMP1.
Chen H; Li L; Hu J; Zhao Z; Ji L; Cheng C; Zhang G; Zhang T; Li Y; Chen H; Pan S; Sun B
J Exp Clin Cancer Res; 2019 Jul; 38(1):297. PubMed ID: 31288830
[TBL] [Abstract][Full Text] [Related]
40. Anti-tumor properties of the cGMP/protein kinase G inhibitor DT3 in pancreatic adenocarcinoma.
Soltek S; Karakhanova S; Golovastova M; D'Haese JG; Serba S; Nachtigall I; Philippov PP; Werner J; Bazhin AV
Naunyn Schmiedebergs Arch Pharmacol; 2015 Nov; 388(11):1121-8. PubMed ID: 26105003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
